Index Entries

David H Canaday, Oladayo A Oyebanji, Debbie Keresztesy, Michael Payne, Dennis Wilk, Lenore Carias, Htin Aung, Kerri St. Denis, Evan C Lam, Christopher F Rowley, Sarah D Berry, Cheryl M Cameron, Mark J Cameron, Brigid M Wilson, Alejandro B Balazs, Christopher L King, and Stefan Gravenstein
November 19, 2021
Clinical Infectious Diseases

Discussion ... In conclusion, these results show the significant loss of potentially protective antibody within 6 months among elderly NH residents following BNT162b2 mRNA vaccination, particularly in those individuals without prior SARS-CoV-2 infection. Our results provide support for the current CDC policy recommending boosters in this older population, and the need for ongoing monitoring to evaluate clinical implications and inform future boosting strategies.

document
adverse events,adverse-event reporting systems,COVID-19,vaccines